A rare inherited neuromuscular disorder (genetically confirmed)
TSR-405 against placebo in an inherited neuromuscular disorder. Sponsor: Tailspin Rare Diseases (fictional), Rare disease.
Which sites are ahead, on target or behind their expectation, where each loses its patients, and what might help.
Sites at a glance
Data to September 30th 2026. Sponsor: Tailspin Rare Diseases (fictional). Study-level KPIs and QTLs have their own tabs: KPIs and QTLs.
Patients randomised
7 of 64
11% of the target
Sites open
18 of 18
Every planned site is open
Patients screened
20
Up: +5 in the last three months
Sites behind their expectation
None judged
Every site is too early to judge: fewer than two patients expected so far
Agreed, of patients approached
45%
55% in published cancer trials
Randomised, of patients screened
35%
The plan assumed 44%
Are enough patients being screened?
Over the last three months the study screened about two patients a month; since it began, 35% of patients screened have been randomised. Randomising the remaining 57 by the planned last patient in March 2027 takes about 33 screens a month, 19.5 times the recent pace. At the recent pace the target is more than two years beyond the planned date. That calls for a decision about the study, such as adding sites or countries, not site-by-site fixes.
Screening is behind the plan
Patients screenedCumulative, against the screens the plan implies: its expected randomisations divided by the 44% it expects to pass screening
Show data
| Month | Planned | Actual |
|---|---|---|
| Sep 2024 | 0 | 0 |
| Dec 2024 | 0 | 0 |
| Mar 2025 | 0 | 0 |
| Jun 2025 | 1 | 0 |
| Sep 2025 | 4 | 2 |
| Dec 2025 | 10 | 7 |
| Mar 2026 | 17 | 13 |
| Jun 2026 | 24 | 14 |
| Sep 2026 | 32 | 18 |
| Oct 2026 | 34 | 20 |
Sources: epiClinical synthetic screening logs; screen failure by therapeutic area from the planner parameters (D23)
How each kind of site is doing
Each site is compared with what it was expected to recruit in its months open, given its type, track record, country and the protocol. Below 75% of that is behind; above 125% is ahead.
No site has been expected to recruit two patients yet, so none can be judged. Recruitment at this rate takes time to show.
Sites behind, and what might help
No site is behind its expectation.
Every site
Show all 18 sites
| Site | Profile | Months open | Expected | Randomised | Approached | Screened | Passed screening | Standing |
|---|---|---|---|---|---|---|---|---|
| 405-US-01, Seattle | Site new to research | 15.1 | 0.6 | 0 | 3 | 1 | 0% | Too early |
| 405-US-02, Chicago | Community specialist practice | 17.6 | 0.7 | 0 | 1 | 0 | – | Too early |
| 405-US-03, Phoenix | Community specialist practice | 17.0 | 0.6 | 0 | 1 | 0 | – | Too early |
| 405-US-04, Los Angeles | Academic medical centre | 13.2 | 0.7 | 0 | 3 | 2 | 0% | Too early |
| 405-US-05, Nashville | Site new to research | 14.0 | 0.5 | 0 | 1 | 1 | 0% | Too early |
| 405-US-06, Denver | Dedicated research centre | 18.9 | 1.6 | 2 | 6 | 2 | 100% | Too early |
| 405-UK-01, Sheffield | Regional teaching hospital | 13.9 | 1.1 | 0 | 3 | 2 | 0% | Too early |
| 405-UK-02, Cardiff | Regional teaching hospital | 14.1 | 1.1 | 0 | 0 | 0 | – | Too early |
| 405-UK-03, Liverpool | Regional teaching hospital | 16.2 | 0.9 | 0 | 3 | 2 | 0% | Too early |
| 405-UK-04, Edinburgh | Regional teaching hospital | 13.6 | 1.1 | 0 | 2 | 1 | 0% | Too early |
| 405-ES-01, Seville | Academic medical centre | 12.7 | 0.8 | 2 | 4 | 3 | 67% | Too early |
| 405-ES-02, Alicante | Site new to research | 13.6 | 0.7 | 0 | 4 | 0 | – | Too early |
| 405-ES-03, Oviedo | Community hospital | 13.9 | 1.1 | 0 | 2 | 0 | – | Too early |
| 405-PL-01, Olsztyn | Community specialist practice | 11.2 | 0.8 | 0 | 2 | 2 | 0% | Too early |
| 405-PL-02, Kraków | Site new to research | 12.0 | 1.0 | 0 | 2 | 0 | – | Too early |
| 405-TR-01, Istanbul | Academic medical centre | 14.7 | 0.5 | 0 | 0 | 0 | – | Too early |
| 405-IN-01, Lucknow | Site new to research | 12.1 | 0.7 | 2 | 3 | 2 | 100% | Too early |
| 405-IN-02, Chennai | Site new to research | 16.4 | 0.7 | 1 | 4 | 2 | 50% | Too early |
Rules behind this page
- A site that has recruited below this share of its expected count is behind: 75%. epiClinical assumption, between the enrolment flag (0.8) and the point NCI trials rarely recovered from (0.6); about half of sites fall short of plan in practice (11% enrol nobody, 37% under-enrol; Tufts, register S-01).
- A site that has recruited above this share of its expected count is ahead: 125%. epiClinical assumption, set symmetrically to the behind line on a ratio scale (1 ÷ 0.8).
- Patients a site must have been expected to recruit before it is judged: 2. epiClinical assumption: below this, a site's count says more about chance than about the site.
- Patients offered a trial who agree to take part: 55%. 55.0% of patients offered a cancer treatment trial agreed, across 35 studies (Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155).
- Patients needed at a funnel stage before a site's rate there is compared with the study's: 8. epiClinical assumption: with fewer, a single patient moves the rate by more than ten points.
- A site's rate at a funnel stage is out of line when so poor a rate would happen by chance less often than this: 0.1. epiClinical assumption: a loose screen, because it prompts a look at the screening log rather than a judgement.
- Patients fail screening: Screen failure is high and varies widely by therapeutic area (register PM-05); restrictive criteria are the commonest design barrier (PB-02, PD-01).
- Patients wait too long for scans: epiClinical assumption from CRA practice; procedures per protocol rose 40.6% since 2010, which weighs on sites without services on site (register S-24).
- Too little coordinator time: Coordinator turnover of 10 to 37% a year, rising to 35 to 61% in 2022; 45% of sites say capacity limits new studies (register S-09, S-11).
- Competing trials take the same patients: Competing trials for the same patients reduce enrolment where the eligible pool is scarce (register EB-02, S-21).
- Too few patients referred: Research-focused sites recruit about 41% better, but depend on referral routes (register S-07); referral networks lack outcome evidence (action A14).
- Patients decline because of the journey: Procedural and visit burden lowers enrolment and retention (register PD-03); decentralised elements help mainly where travel is the barrier (PD-20).